- Home
- LOPE vs BPMC Comparison
LOPE vs BPMC Comparison
Compare LOPE & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOPE
- BPMC
- Stock Information
- Founded
- LOPE 1949
- BPMC 2008
- Country
- LOPE United States
- BPMC United States
- Employees
- LOPE N/A
- BPMC N/A
- Industry
- LOPE Other Consumer Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- LOPE Real Estate
- BPMC Health Care
- Exchange
- LOPE Nasdaq
- BPMC Nasdaq
- Market Cap
- LOPE 5.3B
- BPMC 5.8B
- IPO Year
- LOPE 2008
- BPMC 2015
- Fundamental
- Price
- LOPE $174.32
- BPMC $84.69
- Analyst Decision
- LOPE Buy
- BPMC Buy
- Analyst Count
- LOPE 3
- BPMC 22
- Target Price
- LOPE $197.67
- BPMC $124.48
- AVG Volume (30 Days)
- LOPE 271.3K
- BPMC 1.2M
- Earning Date
- LOPE 05-06-2025
- BPMC 05-01-2025
- Dividend Yield
- LOPE N/A
- BPMC N/A
- EPS Growth
- LOPE 13.68
- BPMC N/A
- EPS
- LOPE 7.73
- BPMC N/A
- Revenue
- LOPE $1,033,002,000.00
- BPMC $508,824,000.00
- Revenue This Year
- LOPE $7.45
- BPMC $45.70
- Revenue Next Year
- LOPE $6.67
- BPMC $31.83
- P/E Ratio
- LOPE $22.58
- BPMC N/A
- Revenue Growth
- LOPE 7.50
- BPMC 104.04
- 52 Week Low
- LOPE $126.17
- BPMC $73.04
- 52 Week High
- LOPE $192.18
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- LOPE 51.11
- BPMC 47.15
- Support Level
- LOPE $160.65
- BPMC $78.66
- Resistance Level
- LOPE $175.17
- BPMC $83.50
- Average True Range (ATR)
- LOPE 6.88
- BPMC 5.00
- MACD
- LOPE 0.66
- BPMC 0.20
- Stochastic Oscillator
- LOPE 69.13
- BPMC 67.15
About LOPE Grand Canyon Education Inc.
Grand Canyon Education, Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's most significant university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases and certificates across nine colleges both online, on ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.